[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Q32 Bio Inc (QTTB)

Q32 Bio Inc (QTTB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Q32 Bio Announces $55 Million Private Placement Financing

WALTHAM, Mass. , May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia...

QTTB : 13.09 (+3.89%)
Q32 Bio: Q1 Earnings Snapshot

Q32 Bio: Q1 Earnings Snapshot

QTTB : 13.09 (+3.89%)
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 --

QTTB : 13.09 (+3.89%)
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass. , April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...

QTTB : 13.09 (+3.89%)
Q32 Bio: Q4 Earnings Snapshot

Q32 Bio: Q4 Earnings Snapshot

QTTB : 13.09 (+3.89%)
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 --

QTTB : 13.09 (+3.89%)
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

WALTHAM, Mass. , Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...

QTTB : 13.09 (+3.89%)
Q32 Bio Announces $10.5 Million Registered Direct Offering

WALTHAM, Mass. , Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...

QTTB : 13.09 (+3.89%)
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?

Q32 Bio stock soared after the biotech firm divested its ADX-097 to Akebia Therapeutics for $12 million. Here’s how you should play QTTB shares heading into 2026.

QTTB : 13.09 (+3.89%)
AKBA : 1.2400 (+2.48%)
Q32 Bio Sells Complement Inhibitor ADX-097

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --

AKBA : 1.2400 (+2.48%)
QTTB : 13.09 (+3.89%)

Barchart Exclusives

Why Analysts Think Rocket Lab Stock Can Gain Another 50% from Here
Rocket Lab could likely soar 50% from this level even though the competition heats up. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.